# All APIs Enhancement Plan - Balanced System

**Goal:** Enhance all 5 APIs with massive datasets for balanced 7 Axes performance  
**Current Status:** Only LexAPI_Genomics enhanced, others using basic data  
**Target:** All APIs using production datasets and cross-axis connections

---

## ENHANCEMENT PRIORITY ORDER

### ðŸ¥‡ **IMMEDIATE: LexAPI_Metabolics Enhancement**
**Current Data:** Basic multi_omics.duckdb (25.5 MB)  
**Available Enhancement:** PharmGKB data (75 MB) + GTEx metabolic data

**Enhancement Targets:**
- **drug_gene_interactions.csv:** Direct drug-gene connections
- **pharmgkb/*.zip files:** Comprehensive pharmacogenomic data
- **GTEx metabolic pathways:** Tissue-specific metabolic analysis
- **Cross-axis:** Connect to genomics protein data

**Expected Impact:** Enable true pharmacogenomic analysis

---

### ðŸ¥ˆ **HIGH PRIORITY: LexAPI_Anatomics Enhancement**  
**Current Data:** Neo4j + digital_twin.duckdb (26 MB)  
**Available Enhancement:** GTEx tissue data + anatomical ontologies

**Enhancement Targets:**
- **GTEx tissue expression:** Connect genes to anatomical locations
- **Ontology files:** UBERON, FMA anatomical structures (global/ontologies/)
- **Cross-axis:** Enhanced gene-anatomy connections
- **Digital twin tables:** Full physiological simulation data

**Expected Impact:** Complete anatomical analysis with gene-tissue mapping

---

### ðŸ¥ˆ **HIGH PRIORITY: LexAPI_Populomics Enhancement**
**Current Data:** Basic population_risk.duckdb (3 MB)  
**Available Enhancement:** gnomAD population data (26.88 GB)

**Enhancement Targets:**
- **gnomAD data:** Population variant frequencies and constraints
- **Population genetics:** Ancestry-specific variant analysis  
- **Environmental data:** Enhanced risk modeling
- **Cross-axis:** Connect to genomics variant frequencies

**Expected Impact:** True population genetics and environmental analysis

---

### ðŸ¥‰ **MEDIUM PRIORITY: LexAPI_Literature Enhancement**
**Current Data:** Basic Qdrant collections  
**Available Enhancement:** Expanded literature collections + cross-API integration

**Enhancement Targets:**
- **Papers directory:** Additional literature sources
- **Cross-API synthesis:** Real-time integration with other APIs
- **Enhanced semantic search:** Better literature analysis
- **Knowledge synthesis:** True cross-axis literature connections

**Expected Impact:** Intelligent literature synthesis with domain context

---

## IMPLEMENTATION STRATEGY

### Week 1: LexAPI_Metabolics (Pharmacogenomics Powerhouse)
- **Day 1-2:** Integrate PharmGKB drug-gene interactions
- **Day 3-4:** Add comprehensive pharmacogenomic analysis
- **Day 5-7:** Test and optimize metabolic cross-axis connections

### Week 2: LexAPI_Anatomics (Anatomical Intelligence)
- **Day 1-3:** Enhance gene-anatomy connections with GTEx data
- **Day 4-5:** Integrate anatomical ontologies from global/
- **Day 6-7:** Test comprehensive anatomical analysis

### Week 3: LexAPI_Populomics (Population Genetics)
- **Day 1-4:** Integrate gnomAD population data (carefully - 26 GB)
- **Day 5-7:** Test population genetics and environmental analysis

### Week 4: LexAPI_Literature + System Integration
- **Day 1-3:** Enhance literature collections and cross-API integration
- **Day 4-7:** Test complete 5-API enhanced system

---

## EXPECTED FINAL PERFORMANCE

### Enhanced System Capabilities
- **LexAPI_Genomics:** 4.4B+ rows, complete genetic analysis âœ…
- **LexAPI_Metabolics:** Comprehensive pharmacogenomics + drug interactions
- **LexAPI_Anatomics:** Complete gene-anatomy mapping + physiological data
- **LexAPI_Populomics:** Population genetics + environmental risk analysis
- **LexAPI_Literature:** Intelligent literature synthesis with domain context

### Benchmark Improvement Prediction
- **Current (1/5 enhanced):** 74.3%
- **After 2/5 enhanced:** 80%+
- **After 3/5 enhanced:** 85%+
- **After 5/5 enhanced:** 90%+ (true 7 Axes system)

**OUTCOME:** Balanced, powerful system with comprehensive analysis across all biological axes.

---

**IMMEDIATE NEXT STEP:** Start with LexAPI_Metabolics enhancement using PharmGKB pharmacogenomic data.
